Breast cancer after use of estrogen plus progestin in postmenopausal women

New England Journal of Medicine

Volumn 360, Issue 6, 2009, Pages 573-587

  Chlebowski, Rowan T ^a,p   Kuller, Lewis H ^b   Prentice, Ross L ^c   Stefanick, Marcia L ^d   Manson, Joann E ^e   Gass, Margery ^f   Aragaki, Aaron K ^c   Ockene, Judith K ^g   Lane, Dorothy S ^h   Sarto, Gloria E ⁱ   Rajkovic, Aleksandar ^j   Schenken, Robert ^k   Hendrix, Susan L ^l   Ravdin, Peter M ^m   Rohan, Thomas E ⁿ   Yasmeen, Shagufta ^o   Anderson, Garnet ^c  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF CINCINNATI   (United States)

^g UNIVERSITY OF MASSACHUSETTS   (United States)

^h STONY BROOK UNIVERSITY   (United States)

ⁱ UNIVERSITY OF WISCONSIN MADISON   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^l HUTZEL HOSPITAL   (United States)

^m UNIVERSITY OF TEXAS   (United States)

ⁿ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p HARBOR UCLA MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; PLACEBO; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEALTH SERVICE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; OBSERVATIONAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; WOMEN'S HEALTH; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; EPIDEMIOLOGY; ESTROGEN THERAPY; FOLLOW UP; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; UNITED STATES; UTILIZATION REVIEW;

AGED; BREAST NEOPLASMS; CAUSALITY; DRUG COMBINATIONS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MAMMOGRAPHY; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE; RISK FACTORS; UNITED STATES;

EID: 59749098583     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0807684     Document Type: Article

References (35)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
2. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243-53.
3. Chlebowski RT, Anderson GL, Pettinger M, et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med 2008;168:370-7.
4. Hersh AL, Stefanick ML, Stafford RS. National use of menopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
5. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy with the publication of clinical trial results. Ann Intern Med 2004;140:184-8.
6. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006; 24(33):e49-e50.
7. Ravdin PM, Cronin K, Howlander N, et al. A sharp decrease in breast cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-4.
8. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008;107:427-30.
9. Canfell K, Banks E, Moa AM, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 2008;188:641-4.
10. Allemand H, Seradour B, Weill A, Ricordeau P. Decline in breast cancer incidence in 2005 and 2006 in France: a paradoxical trend. Bull Cancer 2008;95:11-5. (In French.)
11. Zahl PH, Maehlen J. A decline in breast cancer incidence. N Engl J Med 2007;357:510-1.
12. Vaidya JS. Declines in invasive breast cancer and use of menopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2008;100:598-9.
13. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007;9:R28.
14. MacMahon B, Cole P. Is the breast cancer incidence declining? Epidemiology 2008;19:268-9.
15. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-45.
16. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109.
17. Hays J, Hunt JR, Hubbel FA, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol 2003;13:Suppl:S18-S77.
18. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34.
19. Yasmeen S, Romano PS, Pettinger M, et al. Frequency and predictive value of a mammographic recommendation for short-interval follow-up. J Natl Cancer Inst 2003;95:429-36.
20. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-26.
21. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
22. Prentice RL, Chlebowski RT, Stefanick ML, et al. Estrogen plus progestin therapy and breast cancer in recently post-menopausal women. Am J Epidemiol 2008;167:1207-16.
23. Beral V. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-27. [Erratum, Lancet 2003;362:1160.]
24. Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005;294:183-93.
25. Hulley S, Grady B, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
26. Ravdin PM, Cronin KA, Chlebowski RT. A decline in breast-cancer incidence. N Engl J Med 2007;357:513.
27. Robbins AS, Clarke CA. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 2007;25:3437-9.
28. Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA. Declines in invasive breast cancer and use of menopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2007;99:1335-9. [Erratum, J Natl Cancer Inst 2007;99:1493.]
29. Surveillance, Epidemiology and End Results Program home page. (Accessed January 12, 2009, at http://seer.cancer.gov/.)
30. Kuroishi T, Tominaga S, Morimoto T, et al. Tumor growth rate and prognosis of breast cancer mainly detected by mass screening. Jpn J Cancer Res 1990;81:454-62.
31. Tilanus-Linthorst MM, Kriege M, Boetes C, et al. Hereditary breast cancer growth rates and its impact on screening policy. Eur J Cancer 2005;41:1610-7.
32. Peer PG, van Djick JA, Hendriks JH, Holland R, Verbeek AL. Age-dependent growth of primary breast cancer. Cancer 1993;71:3547-51.
33. Health, United States 2006, with chart-book on trends in health of Americans. Table 84. Hyattsville, MD: National Center for Health Statistics, 2006. (DHHS publication no. 2006-1232.)
34. Ryerson AB, Miller JW, Eheman CR, Leadbetter S, White MC. Recent trends in U.S. mammography use from 2000-2006: a population-based analysis. Prev Med 2008;47:477-82.
35. Rao VM, Levin DC, Parker L, Frangos AJ. Recent trends in mammography utilization in the Medicare population: is there a cause for concern? J Am Coll Radiol 2008;5:652-6.